Singapore vs South Africa: Access to anti-retroviral drugs, female
Singapore
84.0%
in 2023
South Africa
84.0%
in 2024
Singapore rank
50th
South Africa rank
50th
Access to anti-retroviral drugs, female over time
- Singapore
- South Africa
How they compare
Singapore currently reports 84.0% against 84.0% in South Africa, a difference of 0.0%.
The two have swapped places 6 times across 24 shared years of data; in 2000 it was Singapore ahead.
Singapore ranks 50th and South Africa ranks 50th of 141 countries.
Across the 3 decades both report, Singapore averaged higher in 2 and South Africa in 1.
Head to head by decade
| Decade | Singapore | South Africa | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 19.9% | 6.1% | 13.8% | Singapore |
| 2010s | 59.6% | 54.6% | 5.0% | Singapore |
| 2020s | 80.8% | 81.2% | 0.5% | South Africa |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Singapore or South Africa?
- Singapore, at 84.0% against 84.0% in South Africa as of 2023.
- What is the difference in access to anti-retroviral drugs, female between Singapore and South Africa?
- 0.0%, with Singapore ahead.
- How many years of comparable data are there for Singapore and South Africa?
- 24 years are reported by both, from 2000 to 2023.
- How do Singapore and South Africa rank globally for access to anti-retroviral drugs, female?
- Singapore ranks 50th and South Africa ranks 50th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.